Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

66
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
66
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

15
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
15
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

365
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
365
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

671
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
671
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

20
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State Actions on Tobacco Prevention and Cessation.

NCSL legisbrief·2018
Same author

Regulating Hemp and Cannabis-Based Products.

NCSL legisbrief·2017
Same author

Addressing Depression.

NCSL legisbrief·2016
Same author

Benefits and Limits of Abuse-Deterrent Painkillers.

NCSL legisbrief·2016
Same author

Electronic cigarettes and alternative nicotine products.

NCSL legisbrief·2014
Same author

Public health department accreditation.

NCSL legisbrief·2013
Same journal

Fresh Approaches to Addressing High Drug Costs.

NCSL legisbrief·2019
Same journal

States Take On Discipline in Preschool Through Third Grade.

NCSL legisbrief·2019
Same journal

Reauthorized Juvenile Justice Act Strengthens Core Protections.

NCSL legisbrief·2019
Same journal

State Work to Counteract Surprise Medical Billing.

NCSL legisbrief·2019
Same journal

Deploying Next Generation 911.

NCSL legisbrief·2019
Same journal

States Help People with Disabilities Get to Work.

NCSL legisbrief·2019
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Treating hepatitis C.

Karmen Hanson

    NCSL Legisbrief
    |December 18, 2014
    PubMed
    Summary
    This summary is machine-generated.

    New hepatitis C treatments are highly effective, curing more individuals than ever. Screening for hepatitis C is covered by Medicare and many insurance plans, making early detection accessible.

    More Related Videos

    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    24.9K
    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    7.5K

    Related Experiment Videos

    Last Updated: Apr 19, 2026

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K
    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    24.9K
    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    7.5K

    Area of Science:

    • Hepatology
    • Infectious Diseases
    • Public Health

    Background:

    • Hepatitis C virus (HCV) infection remains a significant global health concern.
    • Hepatitis C disproportionately affects the Baby Boomer generation, with an estimated 75% of all cases.
    • Effective screening and treatment strategies are crucial for HCV eradication.

    Purpose of the Study:

    • To highlight advancements in hepatitis C treatment efficacy.
    • To emphasize the importance of screening for hepatitis C in at-risk populations.
    • To inform about insurance coverage for hepatitis C screening.

    Main Methods:

    • Review of recent clinical trial data on novel hepatitis C therapies.
    • Analysis of epidemiological data on hepatitis C prevalence among different demographics.
    • Examination of healthcare policy regarding preventive services for hepatitis C.

    Main Results:

    • New therapeutic regimens demonstrate unprecedented cure rates for hepatitis C.
    • The Baby Boomer cohort represents the largest segment of the hepatitis C-infected population.
    • Hepatitis C screening is recognized as a preventive service, often covered by Medicare and insurance without patient cost-sharing.

    Conclusions:

    • Advances in antiviral therapy have transformed hepatitis C management, leading to high cure rates.
    • Targeted screening efforts in Baby Boomers are essential for early diagnosis and treatment.
    • Financial barriers to screening are reduced due to comprehensive insurance coverage, promoting public health initiatives for hepatitis C elimination.